Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

Reciprocal crosstalk between dendritic cells and natural killer cells under the effects of PGE2 in immunity and immunopathology

Cellular & Molecular Immunology volume 10, pages 213–221 (2013)Cite this article

Abstract

The reciprocal activating crosstalk between dendritic cells (DCs) and natural killer (NK) cells plays a pivotal role in regulating immune defense against viruses and tumors. The cytokine-producing capacity, Th-cell polarizing ability and chemokine expression, migration and stimulatory functions of DCs are regulated by activated NK cells. Conversely, the innate and effector functions of NK cells require close interactions with activated DCs. Cell membrane-associated molecules and soluble mediators, including cytokines and prostaglandins (PGs), contribute to the bidirectional crosstalk between DCs and NK cells. One of the most well-known and well-studied PGs is PGE2. Produced by many cell types, PGE2 has been shown to affect various aspects of the immune and inflammatory responses by acting on all components of the immune system. There is emerging evidence that PGE2 plays crucial roles in DC and NK cell biology. Several studies have shown that DCs are not only a source of PGE2, but also a target of its immunomodulatory action in normal immune response and during immune disorders. Although NK cells appear to be unable to produce PGE2, they are described as powerful PGE2-responding cells, as they express all PGE2 E-prostanoid (EP) receptors. Several NK cell functions (lysis, migration, proliferation, cytokine production) are influenced by PGE2. This review highlights the effects of PGE2 on DC–NK cell crosstalk and its subsequent impact on immune regulations in normal and immunopathological processes.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Moretta A . Natural killer cells and dendritic cells: rendezvous in abused tissues. Nat Rev Immunol 2002; 12: 957–964.

    Article  CAS  Google Scholar 

  2. Fernandez NC, Lozier A, Flament C, Ricciardi-Castagnoli P, Bellet D, Suter M et al. Dendritic cells directly trigger NK cell functions: cross-talk relevant in innate anti-tumor immune responses in vivo. Nat Med 1999; 5: 405–411.

    Article  CAS  PubMed  Google Scholar 

  3. Andoniou CE, van Dommelen SL, Voigt V . Interaction between conventional dendritic cells and natural killer cells is integral to the activation of effective antiviral immunity. Nat Immunol 2005; 6: 1011–1019.

    Article  CAS  PubMed  Google Scholar 

  4. Munz C, Steinman RM, Fujii S . Dendritic cell maturation by innate lymphocytes: coordinated stimulation of innate and adaptive immunity. J Exp Med 2005; 202: 203–207.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  5. Luft T, Jefford M, Luetjens P, Toy T, Hochrein H, Masterman KA et al. Functionally distinct dendritic cell populations induced by physiologic stimuli: prostaglandin E2 regulates the migratory capacity of specific DC subsets. Blood 2002; 100: 1362–1372.

    Article  CAS  PubMed  Google Scholar 

  6. Reschner A, Hubert P, Delvenne P, Boniver J, Jacobs N . Innate lymphocyte and dendritic cell cross-talk: a key factor in the regulation of the immune response. Clin Exp Immunol 2008; 152: 219–226.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Moser M . Dendritic cells in immunity and tolerance—do they display opposite functions? Immunity 2003; 19: 5–8.

    Article  CAS  PubMed  Google Scholar 

  8. Morelli AE, Thomson AW . Tolerogenic dendritic cells and the quest for transplant tolerance. Nat Rev Immunol 2007; 7: 610–621.

    Article  CAS  PubMed  Google Scholar 

  9. Torres-Aguilar H, Aguilar-Ruiz SR, González-Pérez G, Munguía R, Bajaña S, Meraz-Ríos MA, et al. Tolerogenic dendritic cells generated with different immunosuppressive cytokines induce antigen-specific anergy and regulatory properties in memory CD4+ T cells. J Immunol 2010; 184: 1765–1775.

    Article  CAS  PubMed  Google Scholar 

  10. Morelli AE, Larregina AT, Shufesky WJ, Zahorchak AF, Logar AJ, Papworth GD et al. Internalization of circulating apoptotic cells by splenic marginal zone dendritic cells: dependence on complement receptors and effect on cytokine production. Blood 2003; 101: 611–620.

    Article  CAS  PubMed  Google Scholar 

  11. Walzer T, Dalod M, Vivier E, Zitvogel L . Natural killer cell–dendritic cell crosstalk in the initiation of immune responses. Expert Opin Biol Ther 2005; 5: S49–S59.

    Article  CAS  PubMed  Google Scholar 

  12. Battistini A . Interferon regulatory factors in hematopoietic cell differentiation and immuneregulation. J Interferon Cytokine Res 2009; 29: 765–780.

    Article  CAS  PubMed  Google Scholar 

  13. Gattoni A, Parlato A, Vangieri B, Bresciani M, Derna R . Interferon-gamma: biologic functions and HCV therapy (type I/II) (2 of 2 parts). Clin Ter 2006; 157: 457–468.

    CAS  PubMed  Google Scholar 

  14. Cooper MA, Fehinger TA, Caligiuri MA . The biology of human natural killer-cell subsets. Trends Immunol 2001; 22: 633–640.

    Article  CAS  PubMed  Google Scholar 

  15. Hayakawa Y, Smyth MJ . CD27 dissects mature NK cells into two subsets with distinct responsiveness and migratory capacity. J Immunol 2006; 176: 1517–1724.

    Article  CAS  PubMed  Google Scholar 

  16. Chong WP, Zhou J, Law HK, Tu W, Lau YL . Natural killer cells become tolerogenic after interaction with apoptotic cells. Eur J Immunol 2010; 40: 1718–1727.

    Article  CAS  PubMed  Google Scholar 

  17. Jacobs B Ullrich E . The interaction of NK cells and dendritic cells in the tumor environment: how to enforce NK cell and DC action under immunosuppressive conditions? Curr Med Chem 2012; 19: 1771–1779.

    Article  CAS  PubMed  Google Scholar 

  18. van Elssen CH, Vanderlocht J, Oth T, Senden-Gijsbers BL, Germeraad WT, Bos GM . Inflammation-restraining effects of prostaglandin E2 on natural killer–dendritic cell (NK–DC) interaction are imprinted during DC maturation. Blood 2011; 118: 2473–2482.

    Article  CAS  PubMed  Google Scholar 

  19. Walzer T, Dalod M, Robbins SH, Zitvogel L, Vivier E . Natural-killer cells and dendritic cells: “l'union fait la force”. Blood 2005; 1: 2252–2258.

    Article  CAS  Google Scholar 

  20. Trinchieri G . Biology of natural killer cells. Adv Immunol 1989; 47: 187–376.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Gerosa F, Baldani-Guerra B, Nisii C, Marchesini V, Carra G, Trinchieri G . Reciprocal activating interaction between natural killer cells and dendritic cells. J Exp Med 2002; 195: 327–333.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Piccioli D, Sbrana S, Melandri E, Valiante NM . Contact-dependent stimulation and inhibition of dendritic cells by natural killer cells. J Exp Med 2002; 195: 335–341.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Ferlazzo G, Tsang ML, Moretta L, Melioli G, Steinman RM, Münz C . Human dendritic cells activate resting natural killer (NK) cells and are recognized via the NKp30 receptor by activated NK cells. J Exp Med 2002; 195: 343–51

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Vitale M, Della Chiesa M, Carlomagno S, Romagnani C, Thiel A, Moretta L et al. The small subset of CD56brightCD16− natural killer cells is selectively responsible for both cell proliferation and interferon-gamma production upon interaction with dendritic cells. Eur J Immunol 2004; 34: 1715–1722.

    Article  CAS  PubMed  Google Scholar 

  25. Della Chiesa MM, Vitale S, Carlomagno G, Ferlazzo L, Moretta A . The natural killer cell-mediated killing of autologous dendritic cells is confined to a cell subset expressing CD94/NKG2A, but lacking inhibitory killer Ig-like receptors. Eur J Immunol 2003; 33: 1657–1666.

    Article  CAS  PubMed  Google Scholar 

  26. Degli-Esposti MA, Smyth MJ . Close encounters of different kinds: dendritic cells and NK cells take centre stage. Nat Rev Immunol 2005; 5: 112–124.

    Article  CAS  PubMed  Google Scholar 

  27. Mailliard RB, Son YI, Redlinger R, Coates PT, Giermasz A, Morel PA et al. Dendritic cells mediate NK cell help for Th1 and CTL responses: two-signal requirement for the induction of NK cell helper function. J Immunol 2003; 171: 2366–2373.

    Article  CAS  PubMed  Google Scholar 

  28. Agaugue S, Marcenaro E, Ferranti B, Moretta L, Moretta A . Human natural killer cells exposed to IL-2, IL-12, IL-18, or IL-4 differently modulate priming of naive T cells by monocyte-derived dendritic cells. Blood 2008; 112: 1776–1783.

    Article  CAS  PubMed  Google Scholar 

  29. Morandi B, Mortara L, Chiossone L, Accolla RS, Mingari MC, Moretta L et al. Dendritic cell editing by activated natural killer cells results in amore protective cancer-specific immune response. PLoS ONE 2012; 7: e39170.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Siddiqui N, Hope J . Differential recruitment and activation of natural killer cell sub-populations by Mycobacterium bovis-infected dendritic cells. Eur J Immunol; e-pub ahead of print 2 November 2012; doi:10.1002/eji.201242736.

    Article  PubMed  CAS  Google Scholar 

  31. Vitale M, Della Chiesa M, Carlomagno S, Pende D, Aricò M, Moretta L et al. NK-dependent DC maturation is mediated by TNFα and IFNγ released upon engagement of the NKp30 triggering receptor. Blood 2005; 106: 566–571.

    Article  CAS  PubMed  Google Scholar 

  32. Morandi B, Mortara L, Carrega P, Cantoni C, Costa G, Accolla RS et al. NK cells provide helper signal for CD8+ T cells by inducing the expression of membrane-bound IL-15 on DCs. Int Immunol 2009; 21: 599–606.

    Article  CAS  PubMed  Google Scholar 

  33. Tilley SL, Coffman TM, Koller BH . Mixed messages: modulation of inflammation and immune responses by prostaglandins and thromboxanes. J Clin Invest 2001; 108: 15–23.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Gualde N, Harizi H . Prostanoids and their receptors that modulate dendritic cell-mediated immunity. Immunol Cell Biol 2004; 82: 353–360.

    Article  CAS  PubMed  Google Scholar 

  35. Harris SG, Padilla J, Koumas L, Ray D, Phipps RP . Prostaglandins as modulators of immunity. Trends Immunol 2002; 23: 144–150.

    Article  CAS  PubMed  Google Scholar 

  36. Phipps RP, Stein SH, Roper RL . A new view of prostaglandin E regulation of the immune response. Immunol Today 1991; 12: 349–352.

    Article  CAS  PubMed  Google Scholar 

  37. Harizi H, Juzan M, Pitard V, Moreau JF, Gualde N . Cyclooxygenase-2-issued prostaglandin E2 enhances the production of endogenous IL-10, which down-regulates dendritic cell functions. J Immunol 2002; 168: 2255–2263.

    Article  CAS  PubMed  Google Scholar 

  38. Harizi H, Juzan M, Moreau JF, Gualde N . Prostaglandins inhibit 5-lipoxygenase-activating protein expression and leukotriene B4 production from dendritic cells via an IL-10-dependent mechanism. J Immunol 2003; 170: 139–146.

    Article  CAS  PubMed  Google Scholar 

  39. Smith WL, DeWitt DL . Biochemistry of prostaglandin endoperoxide H synthase-1 and synthase-2 and their differential susceptibility to nonsteroidal anti-inflammatory drugs. Semin Nephrol 1995; 15: 179–194.

    CAS  PubMed  Google Scholar 

  40. Harizi H, Juzan M, Grosset G, Rashedi M, Gualde N . Dendritic cells issued in vitro from bone marrow produce PGE2 that contributes to the immunomodulation induced by antigen-presenting cells. Cell Immunol 2001; 209: 19–28.

    Article  CAS  PubMed  Google Scholar 

  41. Harizi H, Limem I, Gualde N . CD40 engagement on dendritic cells induces cyclooxygenase-2 and EP2 receptor via p38 and ERK MAPKs. Immunol Cell Biol 2011; 89: 275–282.

    Article  CAS  PubMed  Google Scholar 

  42. Minghetti L, Walsh DT, Levi G, Perry VH . In vivo expression of cyclooxygenase-2 in rat brain following intraparenchymal injection of bacterial endotoxin and inflammatory cytokines. J Neuropathol Exp Neurol 1999; 58: 1184–1191.

    Article  CAS  PubMed  Google Scholar 

  43. Józefowski S, Bobek M, Marcinkiewicz J . Exogenous but not endogenous prostanoids regulate cytokine secretion from murine bone marrow dendritic cells: EP2, DP, and IP but not EP1, EP3, and FP prostanoid receptors are involved. Int Immunopharmacol 2003; 3: 865–878.

    Article  PubMed  CAS  Google Scholar 

  44. Vassiliou E, Jing H, Ganea D . Prostaglandin E2 inhibits TNF-α production in murine bone marrow-derived dendritic cells. Cell Immunol 2003; 223: 120–132.

    Article  CAS  PubMed  Google Scholar 

  45. Fogel-Petrovic M, Long JA, Knight DA, Thompson PT, Upham JW . Activated human dendritic cells express inducible cyclo-oxygenase and synthesize prostaglandin E2 but not prostaglandin D2. Immunol Cell Biol 2004; 82: 47–54.

    Article  CAS  PubMed  Google Scholar 

  46. Whittaker DS, Bahjat KS, Moldawer LL, Clare-Salzler MJ . Autoregulation of human monocyte-derived dendritic cell maturation and IL-12 production by cyclooxygenase-2-mediated prostanoid production. J Immunol 2000; 165: 4298–4304.

    Article  CAS  PubMed  Google Scholar 

  47. Mahic MS, Yaqub CC, Johansson K, Taskén E, Aandahl M . FOXP3+CD4+CD25+ adaptive regulatory T cells express cyclooxygenase-2 and suppress effector T cells by a prostaglandin E2-dependent mechanism. J Immunol 2006; 177: 246–254.

    Article  CAS  PubMed  Google Scholar 

  48. Fedyk ER, Phipps RP . Prostaglandin E2 receptors of the EP2 and EP4 subtypes regulate activation and differentiation of mouse B lymphocytes to IgE-secreting cells. Proc Natl Acad Sci USA 1996; 1: 10978–10983.

    Article  Google Scholar 

  49. Rocca B, Spain LM, Puré E, Langenbach R, Patrono C, FitzGerald GA . Distinct roles of prostaglandin H synthases 1 and 2 in T-cell development. J Clin Invest 1999; 15: 1469–1477.

    Article  Google Scholar 

  50. Harizi H, Grosset C, Gualde N . Prostaglandin E2 modulates dendritic cell function via EP2 and EP4 receptor subtypes. J Leukoc Biol 2003; 73: 756–763.

    Article  CAS  PubMed  Google Scholar 

  51. Russell SW, Pace JL . Both the kind and magnitude of stimulus are important in overcoming the negative regulation of macrophage activation by PGE2. J Leukoc Biol 1984: 35: 291–301.

    Article  CAS  PubMed  Google Scholar 

  52. Sugimoto Y, Narumiya S, Ichikawa A . Distribution and function of prostanoid receptors: studies from knockout mice. Prog Lipid Res 2000; 39: 289–314.

    Article  CAS  PubMed  Google Scholar 

  53. Narumiya S, Sugimoto Y, Ushikubi F . Prostanoid receptors. Physio Rev 1999; 79: 1193–1226.

    Article  CAS  Google Scholar 

  54. Harizi H, Gualde N . Eicosanoids: an emerging role in dendritic cell biology. Arch Immunol Ther Exp (Warsz) 2004; 52: 1–5.

    CAS  Google Scholar 

  55. Vassiliou E, Sharma V, Fedyk ER, Jing H, Sheibanie F, Ganea D . Prostaglandin E2 promotes the survival of bone marrow-derived dendritic cells. J Immunol 2004; 173: 6955–6964.

    Article  CAS  PubMed  Google Scholar 

  56. Scandella E, Men Y, Gillessen S, Forster R, Groettrup M . Prostaglandin E2 is a key factor for CCR7 surface expression and migration of monocyte-derived dendritic cells. Blood 2002; 100: 1354–1361.

    Article  CAS  PubMed  Google Scholar 

  57. Goodwin JS . Are prostaglandins proinflammatory, antiinflammatory, both or neither? J Rheumatol Suppl 1991; 28: 26–29.

    CAS  PubMed  Google Scholar 

  58. Jonuleit H, Kuhn U, Muller G, Steinbrink K, Paragnik L, Schmitt E et al. Proinflammatory cytokines and prostaglandins reduce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur J Immunol 1997; 27: 3135–3142.

    Article  CAS  PubMed  Google Scholar 

  59. Zelle-Rieser C, Ramoner R, Artner-Dworzak E, Casari A, Bartsch G, Thurnher M . Human monocyte-derived dendritic cells are deficient in prostaglandin E2 production. FEBS Lett 2002; 30: 123–126.

    Article  Google Scholar 

  60. Rieser C, Bock G, Klocker H, Bartsch G, Thurnher M . Prostaglandin E2 and tumor necrosis factor α cooperate to activate human dendritic cells: synergistic activation of interleukin 12 production. J Exp Med 1997; 186: 1603–1608.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Jing H, Vassiliou E, Ganea D . Prostaglandin E2 inhibits production of the inflammatory chemokines CCL3 and CCL4 in dendritic cells. J Leukoc Biol 2003; 74: 868–879.

    Article  CAS  PubMed  Google Scholar 

  62. D'Andrea A, Aste-Amezaga M, Valiante M, Ma X, Kubin M, Trinchieri G . Interleukin-10 (IL-10) inhibits human lymphocyte IFNγ production by suppressing natural killer cell stimulatory factor/IL-12 synthesis in accessory cells. J Exp Med 1993; 178: 1041–1048.

    Article  CAS  PubMed  Google Scholar 

  63. Enk AH, Angeloni VL, Udey MC, Katz SI . Inhibition of antigen-presenting function by IL-10. J. Immunol 1993; 151: 2390–2398.

    CAS  PubMed  Google Scholar 

  64. Steinbrink K, Wolfl M, Jonuleit H, Knop J, Enk AH . Induction of tolerance by IL-10-treated dendritic cells. J Immunol 1997; 159: 4772–4780.

    CAS  PubMed  Google Scholar 

  65. Snijdewint FG, Kalinski P, Wierenga EA, Bos JD, Kapsenberg ML . Prostaglandin E2 differentially modulates cytokine secretion profiles of human T helper lymphocytes. J Immunol 1993; 150: 5321–5329.

    CAS  PubMed  Google Scholar 

  66. Kuroda E, Sugiura T, Zeki K, Yoshida Y, Yamashita U . Sensitivity difference to the suppressive effect of prostaglandin E2 among mouse strains: a possible mechanism to polarize Th2 type response in BALB/c mice. J Immunol 2000; 164: 2386–2395.

    Article  CAS  PubMed  Google Scholar 

  67. Nataraj C, Thomas DW, Tilley SL, Nguyen MT, Mannon R, Koller BH et al. Receptors for prostaglandin E2 that regulate cellular immune responses in the mouse. J Clin Invest 2001; 108: 1229–1235.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  68. Kabashima K, Sakata KD, Nagamachi M, Miyachi Y, Inaba K, Narumiya S . Prostaglandin E2–EP4 signaling initiates skin immune responses by promoting migration and maturation of Langerhans cells. Nat Med 2003; 9: 744–749.

    Article  CAS  PubMed  Google Scholar 

  69. Walker W, Rotondo D . Prostaglandin E2 is a potent regulator of interleukin-12- and interleukin-18-induced natural killer cell interferon-gamma synthesis. Immunology 2004; 111: 298–305.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  70. Goto T, Herberman RB, Maluish A, Strong DM . Cyclic AMP as a mediator of prostaglandin E-induced suppression of human natural killer cell activity. J Immunol 1983; 130: 1350–1355.

    CAS  PubMed  Google Scholar 

  71. Vaillier D, Daculsi R, Gualde N . Effect of prostaglandin E2 on cytotoxic activity and granzyme A protease release by murine adherent IL-2 activated killer cells. Immunobiology 1994; 190: 275–289.

    Article  CAS  PubMed  Google Scholar 

  72. Joshi PC, Zhou X, Cuchens M, Jones Q . Prostaglandin E2 suppressed IL-15-mediated human NK cell function through down-regulation of common gamma-chain. J Immunol 2001; 166: 885–891.

    Article  CAS  PubMed  Google Scholar 

  73. Holt DH, Ma X, Kundu N, Collin PD, Fulton AM . Modulation of host natural killer cell functions in breast cancer via prostaglandin E2 receptors EP2 and EP4. J Immunother 2012; 35: 179–188.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  74. Holt DH, Ma X, Kundu N, Fulton AM . Prostaglandin E2 suppresses natural killer cell function primarily through the PGE2 receptor EP4. Cancer Immunol Immunother 2011; 60: 1577–1586.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  75. Martinet L, Jean C, Dietrich D, Fournié JJ, Poupot R . PGE2 inhibits natural killer and gamma delta T cell cytotoxicity triggered by NKR and TCR through a cAMP-mediated PKA type I-dependent signaling. Biochem Pharmacol 2010; 15: 838–845.

    Article  CAS  Google Scholar 

  76. Zeddou M, Rahmouni S, Vandamme A, Jacobs N, Frippiat F, Leonard P et al. Prostaglandin E2 induces the expression of functional inhibitory CD94/NKG2A receptors in human CD8+ T lymphocytes by a cAMP-dependent protein kinase A type I pathway. Biochem Pharmacol 2005; 70: 714–724.

    Article  CAS  PubMed  Google Scholar 

  77. Gustafsson K, Ingelsten M, Bergqvist L, Nystrom J, Andersson B, Karlsson-Parra A . Recruitment and activation of natural killer cells in vitro by a human dendritic cell vaccine. Cancer Res 2008; 68: 5965–597.

    Article  CAS  PubMed  Google Scholar 

  78. Mailliard RB, Alber SM, Shen H, Watkins SC, Kirkwood JM, Herberman RB et al. IL-18-induced CD83+CCR7+ NK helper cells. J Exp Med 2005; 202: 941–953.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  79. Serhan CN, Levy CN . Success of prostaglandin E2 in structure–function is a challenge for structure-based therapeutics. Proc Nat Aca Sci USA 2003; 100: 8609–8611.

    Article  CAS  Google Scholar 

  80. Harizi H, Corcuff JB, Gualde N . Arachidonic-acid-derived eicosanoids: roles in biology and immunopathology. Trends Mol Med 2008; 14: 461–469.

    Article  CAS  PubMed  Google Scholar 

  81. Wang D, Wang DW, Shi Q, Katkuri S, Walhi W, Desvergne B et al. Prostaglandin E2 promotes colorectal adenoma growth via transactivation of the nuclear peroxisome proliferatorsactivated receptor delta. Cancer Cell 2004; 6: 285–295.

    Article  CAS  PubMed  Google Scholar 

  82. Berens ME, Salmon SE, Davis TP . Quantitative analysis of prostaglandins in cell culture medium by high-resolution gas chromatography with electron-capture detection. J Chromatogr 1984; 307: 251–260.

    Article  CAS  PubMed  Google Scholar 

  83. Gately S . The contributions of cyclooxygenase-2 to tumor angiogenesis. Cancer Metastasis Rev 2000; 19: 19–27.

    Article  CAS  PubMed  Google Scholar 

  84. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN . Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998; 29: 705–716.

    Article  Google Scholar 

  85. Yang L, Yamagata N, Yadav R, Brandon S, Courtney RL, Morrow JD et al. Cancer-associated immunodeficiency and dendritic cell abnormalities mediated by the prostaglandin EP2 receptor. J Clin Invest 2003; 111: 727–735.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  86. Kusmartsev S, Gabrilovich DI . Effect of tumor-derived cytokines and growth factors on differentiation and immune suppressive features of myeloid cells in cancer. Cancer Metastasis Rev 2006; 25: 323–331.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  87. Pinzon-Charry A, Maxwell T, Lopez JA . Dendritic cell dysfunction in cancer: a mechanism for immunosuppression. Immunol Cell Biol 2005; 83: 451–461.

    Article  CAS  PubMed  Google Scholar 

  88. Pietra G, Manzini C, Rivara S, Vitale M, Cantoni C, Petretto A et al. Melanoma cells inhibit natural killer cell function by modulating the expression of activating receptors and cytolytic activity. Cancer Res 2012; 15: 1407–1415.

    Article  CAS  Google Scholar 

  89. Kundu N, Walser TC, Ma X, Fulton AM . Cyclooxygenase inhibitors modulate NK activities that control metastatic disease. Cancer Immunol Immunother 2005; 54: 981–987.

    Article  CAS  PubMed  Google Scholar 

  90. Rabinovich GA, Gabrilovich D, Sotomayor EM . Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol 2007; 25: 267–296.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  91. Tsujii M, Kawano S, DuBois RN . Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci USA 1997; 94: 3336–3340.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  92. Simpson JL, Brooks C, Douwes J . Innate immunity in asthma. Paediatr Respir Rev 2008; 9: 263–270.

    Article  PubMed  Google Scholar 

  93. Timonen T, Stenius-Aarniala B . Natural killer cell activity in asthma. Clin Exp Immunol 1985; 59: 85–90.

    CAS  PubMed  PubMed Central  Google Scholar 

  94. Umetsu DT, Dekruyff RH . Natural killer T cells are important in the pathogenesis of asthma: the many pathways to asthma. J Allergy Clin Immunol 2010; 125: 975–979.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  95. Stock P, Akbari O . Recent advances in the role of NKT cells in allergic diseases and asthma. Curr Allergy Asthma Rep 2008; 8: 165–170.

    Article  CAS  PubMed  Google Scholar 

  96. Korsgren M . NK cells and asthma. Curr Pharm Des 2002; 8: 1871–1876.

    Article  CAS  PubMed  Google Scholar 

  97. Schmidt LM, Belvisi MG, Bode KA, Bauer G, Schmidt C, Suchy MT et al. Bronchial epithelial cell-derived prostaglandin E2 dampens the reactivity of dendritic cells. J Immunol 2011; 186: 2095–2105.

    Article  CAS  PubMed  Google Scholar 

  98. Vancheri C, Mastruzzo C, Sortino MA, Crimi N . The lung as a privileged site for the beneficial actions of PGE2. Trends Immunol 2004; 25: 40–46.

    Article  CAS  PubMed  Google Scholar 

  99. Pavord ID, Wong CS, Williams J, Tattersfield AE . Effect of inhaled prostaglandin E2 on allergen-induced asthma. Am RevRespir Dis 1993; 148: 87–90.

    Article  CAS  Google Scholar 

  100. Tilley SL, Hartney JM, Erikson CJ, Jania C, Nguyen M, Stock J et al. Receptors and pathways mediating the effects of prostaglandin E2 on airway tone. Am J Physiol Lung Cell Mol Physiol 2003; 284: 599–606.

    Article  Google Scholar 

  101. Biron CA Brossay L . NK cells and NKT cells in innate defense against viral infections. Curr Opin Immunol 2001; 13: 458–464.

    Article  CAS  PubMed  Google Scholar 

  102. Andrews DM, Scalzo AA, Yokoyama WM . Functional interactions between dendritic cells and NK cells during viral infection. Nat Immunol 2003; 4: 175–181.

    Article  CAS  PubMed  Google Scholar 

  103. Wang D, Dubois RN . Prostaglandins and cancer. Gut 2006; 55: 115–122.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  104. Balch CM, Dougherty PA, Cloud GA, Tilden AB . Prostaglandin E2-mediated suppression of cellular immunity in colon cancer patients. Surgery 1984; 95: 71–77.

    CAS  PubMed  Google Scholar 

  105. Vane JR . Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 1971; 231: 232–235.

    Article  CAS  PubMed  Google Scholar 

  106. Khanapure SP, Garvey DS, Janero DR, Letts LG . Eicosanoids in inflammation: biosynthesis, pharmacology, and therapeutic frontiers. Curr Top Med.Chem 2007; 7: 311–340.

    Article  CAS  PubMed  Google Scholar 

  107. Méric JB, Rottey S, Olaussen K, Soria JC, Khayat D, Rixe O et al. Cyclooxygenase-2 as a target for anticancer drug development. Crit Rev Oncol Hematol 2006; 59: 51–64.

    Article  PubMed  Google Scholar 

  108. Eisenthal A . Indomethacin up-regulates the generation of lymphokine activated killer cell activity and antibody-dependent cellular toxicity mediated by interleukin-2. Cancer Immunol. Immunother 1990; 31: 342–348.

    Article  CAS  PubMed  Google Scholar 

  109. Hussain M, Javeed A, Ashraf M, Al-Zaubai N, Stewart A, Mukhtar MM . Non-steroidal anti-inflammatory drugs, tumour immunity and immunotherapy. Pharmacol Res 2012; 66: 7–18.

    Article  CAS  PubMed  Google Scholar 

  110. Robak P, Smolewski P, Robak T . The role of non-steroidal anti-inflammatory drugs in the risk of development and treatment of hematologic malignancies. Leuk Lymphoma 2008; 2: 1–11.

    Google Scholar 

  111. Agrawal A, Fentiman IS . NSAIDs and breast cancer: a possible prevention and treatment strategy. Int J Clin Pract 2008; 62: 444–449.

    Article  CAS  PubMed  Google Scholar 

  112. Hahn T, Alvarez I, Kobie JJ, Ramanathapuram L, Dial S, Fulton A et al. Short-term dietary administration of celecoxib enhances the efficacy of tumor lysate-pulsed dendritic cell vaccines in treating murine breast cancer. Int J Cancer 2006; 118: 2220–2231.

    Article  CAS  PubMed  Google Scholar 

  113. Haas AR, Sun J, Vachani A, Wallace AF, Silverberg M, Kapoor V et al. Cycloxygenase-2 inhibition augments the efficacy of a cancer vaccine. Clin Cancer Res 2006; 12: 214–222.

    Article  CAS  PubMed  Google Scholar 

  114. Marnett LJ . The COXIB experience: a look in the rearview mirror. Annu Rev Pharmacol Toxicol 2009; 49: 265–290.

    Article  CAS  PubMed  Google Scholar 

  115. Wang D, Wang M, Cheng Y, Fitzgerald GA . Cardiovascular hazard and nonsteroidal anti-inflammatory drugs. Curr Opin Pharmacol 2005; 5: 204–210.

    Article  CAS  PubMed  Google Scholar 

  116. Mosenden R, Tasken K . Cyclic AMP-mediated immune regulation—overview of mechanisms of action in T cells. Cell Signal 2010; 23: 1009–1016.

    Article  PubMed  CAS  Google Scholar 

  117. Jones RL, Giembycz MA, Woodward DF . Prostanoid receptor antagonists: development strategies and therapeutic applications. Br J Pharmacol 2009; 158: 104–45.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  118. Af Forselles K, Root J, Clarke T, Davey D, Aughton K, Dack K . In vitro and in vivo characterization of PF-04418948, a novel, potent and selective prostaglandin EP2 receptor antagonist. Br J Pharmacol 2011; 164: 1847–5186.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  119. Makita H, Mutoh M, Maruyama T, Yonemoto K, Kobayashi A, Fujitsuka H . A prostaglandin E2 receptor subtype EP1-selective antagonist, ONO-8711, suppresses 4-nitroquinoline 1-oxide-induced rat tongue carcinogenesis. Carcinogenesis 2007; 28: 677–84.

    Article  CAS  PubMed  Google Scholar 

  120. Niho N, Mutoh M, Kitamura T, Takahashi M, Sato H, Yamamoto H . Suppression of azoxymethane-induced colon cancer development in rats by a prostaglandin E receptor EP1-selective antagonist. Cancer Sci 2005; 96: 260–264.

    Article  CAS  PubMed  Google Scholar 

  121. Hoshikawa H, Goto R, Mori T, Mitani T, Mori N . Expression of prostaglandin E2 receptors in oral squamous cell carcinomas and growth inhibitory effects of an EP3 selective antagonist, ONO-AE3-240. Int J Oncol 2009; 34: 847–852.

    Article  CAS  PubMed  Google Scholar 

  122. Kundu N, Ma X, Holt D, Goloubeva O, Ostrand-Rosenberg S, Fulton AM . Antagonism of the prostaglandin E receptor EP4 inhibits metastasis and enhances NK function. Breast Cancer Res Treat 2009; 117: 235–242.

    Article  CAS  PubMed  Google Scholar 

  123. Ma X, Kundu N, Rifat S, Walser T, Fulton AM . Prostaglandin E receptor EP4 antagonism inhibits breast cancer metastasis. Cancer Res 2006; 66: 2923–2927.

    Article  CAS  PubMed  Google Scholar 

  124. Ma X, Kundu N, Collin P, Goloubeva O, Fulton AM . Frondoside A inhibits breast cancer metastasis and antagonizes prostaglandin E receptors EP4 and EP2. Breast Cancer Res Treat 2011; 132: 1001–1008.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

Download references

Acknowledgements

This work was supported by the Regional League against Cancer: Departmental Committee of Gironde and Charentes.

Author information

Authors and Affiliations

  1. Laboratory of Immunology, Mixed Research Unit 5540, Bordeaux 2 University, Bordeaux, France

    Hedi Harizi

Authors
  1. Hedi Harizi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hedi Harizi.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Harizi, H. Reciprocal crosstalk between dendritic cells and natural killer cells under the effects of PGE2 in immunity and immunopathology. Cell Mol Immunol 10, 213–221 (2013). https://doi.org/10.1038/cmi.2013.1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/cmi.2013.1

Keywords

This article is cited by

Search

Advanced search

Quick links